Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant - Comparison with flecainide

European Journal of Pharmacology

Volumn 724, Issue 1, 2014, Pages 51-57

  Seyler, Claudia ^a   Li, Jin ^a   Schweizer, Patrick A ^a   Katus, Hugo A ^a   Thomas, Dierk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Cardiac arrhythmia; Flecainide; K2P channel; Vernakalant

Indexed keywords

FLECAINIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL K2P; UNCLASSIFIED DRUG; VERNAKALANT;

ANIMAL CELL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CHANNEL GATING; CHINESE HAMSTER; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEART ELECTROPHYSIOLOGY; HUMAN; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; POTASSIUM CURRENT; PRIORITY JOURNAL; VOLTAGE CLAMP TECHNIQUE; WHOLE CELL PATCH CLAMP; XENOPUS;

ANTIARRHYTHMIC DRUG; ATRIAL FIBRILLATION; CARDIAC ARRHYTHMIA; FLECAINIDE; K(2P) CHANNEL; VERNAKALANT;

ANIMALS; ANISOLES; ANTI-ARRHYTHMIA AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; FLECAINIDE; HUMANS; OOCYTES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PYRROLIDINES; XENOPUS LAEVIS;

EID: 84891770244     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.12.030     Document Type: Article

References (45)

1. A. Burashnikov, M. Pourrier, J.K. Gibson, J.J. Lynch, and C. Antzelevitch Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol Circ. Arrhythm. Electrophysiol. 5 2012 400 408
2. A.J. Camm, A. Capucci, S.H. Hohnloser, C. Torp-Pedersen, I.C. Van Gelder, B. Mangal, G. Beatch AVRO Investigators A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation J. Am. Coll. Cardiol. 57 2011 313 321
3. N. Decher, K. Wemhöner, S. Rinné, M.F. Netter, M. Zuzarte, M.I. Aller, S.G. Kaufmann, X.T. Li, S.G. Meuth, J. Daut, F.B. Sachse, and S.K. Maier Knock-out of the potassium channel TASK-1 leads to a prolonged QT interval and a disturbed QRS complex Cell. Physiol. Biochem. 28 2011 77 86
4. D. Dobrev, B. Hamad, and P. Kirkpatrick Vernakalant Nat. Rev. Drug. Discov. 9 2010 915 916
5. D. Dobrev, and S. Nattel New antiarrhythmic drugs for treatment of atrial fibrillation Lancet 375 2010 1212 1223
6. P. Dorian, A. Pinter, I. Mangat, V. Korley, S.S. Cvitkovic, and G.N. Beatch The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans J. Cardiovasc. Pharmacol. 50 2007 35 40 (Pubitemid 47220444)
7. C.Y. Du, A. El Harchi, Y.H. Zhang, C.H. Orchard, and J.C. Hancox Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis J. Cardiovasc. Electrophysiol. 22 2011 1163 1170
8. J.R. Ehrlich, P. Biliczki, S.H. Hohnloser, and S. Nattel Atrial-selective approaches for the treatment of atrial fibrillation J. Am. Coll. Cardiol. 51 2008 787 792 (Pubitemid 351253743)
9. P. Enyedi, and G. Czirjak Molecular background of leak K+ currents: two-pore-domain potassium channels Physiol. Rev. 90 2010 559 605
10. D. Fedida Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent Expert Opin. Investig. Drugs 16 2007 519 532 (Pubitemid 46554469)
11. D. Fedida, P.M. Orth, J.Y. Chen, S. Lin, B. Plouvier, G. Jung, A.M. Ezrin, and G.N. Beatch The mechanism of atrial antiarrhythmic action of RSD1235 J. Cardiovasc. Electrophysiol. 16 2005 1227 1238
12. 2P) potassium leak channels by the tyrosine kinase inhibitor genistein Br. J. Pharmacol. 154 2008 1680 1690
13. 2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone Naunyn-Schmiedebergs Arch. Pharmacol. 381 2010 261 270
14. 2P10.1 (TREK2) two-pore-domain K+ channels BBA - Biomembr. 1818 2012 33 41
15. S.A. Goldstein, D. Bockenhauer, I. O'Kelly, and N. Zilberberg Potassium leak channels and the KCNK family of two-P-domain subunits Nat. Rev. Neurosci. 2 2001 175 184 (Pubitemid 33673370)
16. L. Goonetilleke, and J. Quayle TREK-1 K+ channels in the cardiovascular system: their significance and potential as therapeutic target Cardiovasc. Ther. 30 2012 e23 e29
17. R.R. Kowey, P. Dorian, L.B. Mitchell, C.M. Pratt, D. Roy, P.J. Schwartz, J. Sadowski, D. Sobczyk, A. Bochenek, E. Toft Atrial Arrhythmia Conversion Trial Investigators Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial Circ. Arrhythm. Electrophysiol. 2 2009 652 659
18. E. Marban Cardiac channelopathies Nature 415 2002 213 218 (Pubitemid 34059527)
19. S. Obers, I. Staudacher, E. Ficker, A. Dennis, R. Koschny, H. Erdal, R. Bloehs, J. Kisselbach, C.A. Karle, P.A. Schweizer, H.A. Katus, and D. Thomas Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine Naunyn Schmiedebergs Arch. Pharmacol. 381 2010 385 400
20. P.M. Orth, J.C. Hesketh, C.K. Mak, Y. Yang, S. Lin, G.N. Beatch, A.M. Ezrin, and D. Fedida RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents Cardiovasc. Res. 70 2006 486 496
21. J.R. Penniman, D.C. Kim, J.J. Salata, and J.P. Imredy Assessing use-dependent inhibition of the cardiac Na(±) current (I(Na)) in the PatchXpress automated patch clamp J. Pharmacol. Toxicol. Methods 62 2010 107 118
22. S. Petric, L. Clasen, C. van Wessel, N. Geduldig, Z. Ding, M. Schullenberg, J. Mersmann, K. Zacharowski, M.I. Aller, K.G. Schmidt, and B.C. Donner In vivo electrophysiological characterization of TASK-1 deficient mice Cell. Physiol. Biochem. 30 2012 523 537
23. C.M. Pratt, D. Roy, C. Torp-Pedersen, D.G. Wyse, E. Toft, S. Juul-Moller, E. Retyk, D.H. Drenning Atrial Arrhythmia Conversion Trial (ACT-III) Investigators Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation Am. J. Cardiol. 106 2010 1277 1283
24. + channels Br. J. Pharmacol. 166 2012 764 773
25. U. Ravens Novel pharmacological approaches for antiarrhythmic therapy Naunyn Schmiedebergs Arch. Pharmacol. 381 2010 187 193
26. + channels Naunyn Schmiedebergs Arch. Pharmacol. 2013 10.1007/s00210-013-0945-1
27. U. Ravens, C. Poulet, E. Wettwer, and M. Knaut Atrial selectivity of antiarrhythmic drugs J. Physiol. 591 2013 4087 4097
28. D. Roy, B.H. Rowe, I.G. Stiell, B. Coutu, J.H. Ip, D. Phaneuf, J. Lee, H. Vidaillet, G. Dickinson, S. Grant, A.M. Ezrin, G.N. Beatch CRAFT Investigators A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation J. Am. Coll. Cardiol. 44 2004 2355 2361 (Pubitemid 39647610)
29. D. Roy, C.M. Pratt, C. Torp-Pedersen, D.G. Wyse, E. Toft, S. Juul-Moller, T. Nielsen, S.L. Rasmussen, I.G. Stiell, B. Coutu, J.H. Ip, E.L. Pritchett, A.J. Camm Atrial Arrhythmia Conversion Trial Investigators Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial Circulation 117 2008 1518 1525 (Pubitemid 351440640)
30. 2P) channels Naunyn Schmiedebergs Arch. Pharmacol. 385 2012 1003 1016
31. 2P) channels Eur. J. Pharmacol. 721 2013 237 248
32. + channels in a porcine model Life Sci. 2013 10.1016/j.lfs.2013.12.006
33. + current inhibition by endothelin-1 is mediated by Rho kinase-dependent channel phosphorylation Br. J. Pharmacol. 165 2012 1467 1475
34. S. Sicouri, M. Pourrier, J.K. Gibson, J.J. Lynch, and C. Antzelevitch Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations Heart Rhythm 9 2012 422 429
35. M.T. Slawsky, and N.A. Castle K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes J. Pharmacol. Exp. Ther. 269 1994 66 74 (Pubitemid 24143236)
36. + channels J. Physiol. 589 2011 3709 3720
37. 2P3.1 (TASK1) K+ leak channels Br. J. Pharmacol. 163 2011 1099 1110
38. I. Staudacher, L. Wang, X. Wan, S. Obers, W. Wenzel, F. Tristram, R. Koschny, K. Staudacher, J. Kisselbach, P. Koelsch, P.A. Schweizer, H.A. Katus, E. Ficker, and D. Thomas hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine Naunyn Schmiedebergs Arch. Pharmacol. 383 2011 119 139
39. I.G. Stiell, J.S. Roos, K.M. Kavanagh, and G. Dickinson A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm Am. Heart J. 159 2010 1095 1101
40. D. Thomas, B. Gut, S. Karsai, A.B. Wimmer, K. Wu, G. Wendt-Nordahl, W. Zhang, S. Kathöfer, W. Schoels, H.A. Katus, J. Kiehn, and C.A. Karle Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen Naunyn Schmiedebergs Arch. Pharmacol. 368 2003 41 48 (Pubitemid 36960483)
41. D. Thomas, B.C. Hammerling, A.B. Wimmer, K. Wu, E. Ficker, Y.A. Kuryshev, D. Scherer, J. Kiehn, H.A. Katus, W. Schoels, and C.A. Karle Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X) Cardiovasc. Res. 64 2004 467 476 (Pubitemid 39505425)
42. D. Thomas, A.B. Wimmer, K. Wu, B.C. Hammerling, E.K. Ficker, Y.A. Kuryshev, J. Kiehn, H.A. Katus, W. Schoels, and C.A. Karle Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin Naunyn Schmiedebergs Arch. Pharmacol. 369 2004 462 472 (Pubitemid 38669965)
43. 2P2.1 potassium channels permeable to sodium Neuron 58 2008 859 870 (Pubitemid 351842748)
44. Z. Wang, B. Fermini, and S. Nattel Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes J. Pharmacol. Exp. Ther. 272 1995 184 196
45. E. Wettwer, T. Christ, S. Endig, N. Rozmaritsa, K. Matschke, J.J. Lynch, M. Pourrier, J.K. Gibson, D. Fedida, M. Knaut, and U. Ravens The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation Cardiovasc. Res. 98 2013 145 154